Why Ventas (VTR) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Zacks·18d ago
More News
Ventas Stock Gains 15.5% Year to Date: Will It Continue to Rise?
VTR stock rallies 15.5% YTD as strong SHOP growth, accretive investments and a solid balance sheet fuel momentum.
Zacks·19d ago
Here's Why You Should Retain Welltower Stock in Your Portfolio Now
WELL's seniors housing operating portfolio is set to benefit from the aging population and rising healthcare spending. However, high competition is a concern.
Zacks·24d ago
Ventas Selects Discovery Senior Living to Operate its 15 Communities
VTR taps Discovery Senior Living to run 15 communities, expanding a partnership aimed at boosting performance and value creation.
Zacks·27d ago
Ventas (VTR) Could Be a Great Choice
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes? Let's find out.
Zacks·1mo ago
Ventas Q2 FFO and Revenues Top Estimates, Same-Store Cash NOI Rises
VTR's Q2 results reflect a year-over-year rise in revenues. The total property same-store NOI improves on strong performance across the business segments.
Zacks·1mo ago
Ventas (VTR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Ventas (VTR) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·1mo ago
Ventas (VTR) Beats Q2 FFO and Revenue Estimates
Ventas (VTR) delivered FFO and revenue surprises of +2.35% and +3.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
Ahead of Ventas (VTR) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Ventas (VTR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Zacks·1mo ago
Healthpeak Q2 FFO Meets Estimates, Same-Store NOI Rises Y/Y
DOC's second-quarter results reflect the continued strong performance of its high-quality lab, outpatient medical and CCRC portfolios.